Pluvicto for prostate cancer with kidney or marrow issues
Part of Blood & lymphatic, Cancer, Kidney & urinary clinical trials.
This trial studies how well a radioactive drug called Pluvicto works in men with prostate cancer who also have kidney or bone marrow problems. You'll get the treatment and have several scans to see how the drug affects your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be approved for Pluvicto therapy (a radioactive treatment for prostate cancer).
- You must have kidney problems (GFR between 30 and 50) or low blood counts (low white blood cells or platelets).
- You must be willing to have multiple imaging scans during the study.
- This trial is for men with prostate cancer (women and children are not eligible).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This study looks at how well Pluvicto, a targeted radiation therapy for advanced prostate cancer, works in real-world patients. It aims to learn more about survival outcomes for people like you.
This trial tests whether the drug Pluvicto (also known as lutetium Lu 177 vipivotide tetraxetan) can help African American men with a type of prostate cancer that has spread and no longer responds to hormone therapy. The treatment targets a protein called PSMA found on cancer cells, which may slow the cancer's growth.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
Hear when a new Lu-177 PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.